Shuttle Pharmaceuticals

20 articles about Shuttle Pharmaceuticals

• Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

  4/3/2024

  Shuttle Pharmaceuticals Holdings, Inc. today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference.

• Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

  3/5/2024

  Shuttle Pharmaceuticals Holdings, Inc. today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on March 6, 2024.

• Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

  2/13/2024

  Shuttle Pharmaceuticals Holdings, Inc. today announced its intent to commence a Rights Offering where it plans to raise up to $4.5 million through the distribution of subscription rights and the exercise thereof, which full rights will entitle existing SHPH stockholders to purchase from the Company units (the "Units"), with each Unit consisting of (i) one share of SHPH common stock.

• Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

  1/8/2024

  Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced they have received the 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for the Company's investigational new drug (IND) application for its Phase II study of Ropidoxuridine.

• Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

  12/11/2023

  Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma") today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to support the next phase of development of Ropidoxuridine.

• Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

  11/30/2023

  Shuttle Pharmaceuticals Holdings, Inc. today announced that its Chief Executive Officer, Dr. Anatoly Dritschilo, will be participating in the Emerging Growth Conference on December 7, 2023 (the "Conference").

• Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

  11/14/2023

  Shuttle Pharmaceuticals Holdings, Inc. today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

• Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

  10/10/2023

  Shuttle Pharmaceuticals Holdings, Inc. announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

• Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

  9/25/2023

  Shuttle Pharmaceuticals Holdings, Inc. today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application (PIND) meeting with the U.S. Food and Drug Administration (FDA).

• Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

  8/15/2023

  Shuttle Pharmaceuticals Holdings, Inc. today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.

• Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

  8/3/2023

  Shuttle Pharmaceuticals Holdings, Inc. announced that TCG GreenChem has successfully completed the initial manufacturing campaign for the active pharmaceutical ingredient of Ropidoxuridine for use in the Company's upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy.

• Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

  5/26/2023

  Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.

• Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

  5/17/2023

  Shuttle Pharmaceuticals Holdings, Inc. announced today that its Chief Executive Officer, Anatoly Dritschilo , M.D., will be participating in a Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference (the "Conference") on Thursday, May 18, 2023.

• Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

  1/12/2023

  Shuttle Pharmaceuticals Holdings, Inc. announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor.

• Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

  12/6/2022

  Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy, announced the publication of a manuscript discussing prostate cancer cell lines derived from African American men for precision medicine.

• Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"

  8/31/2022

  Shuttle Pharmaceuticals Holdings, Inc. is pleased to announce the Company's shares of common stock has commenced trading on The Nasdaq Capital Market under the ticker symbol "SHPH".

• Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering

  8/30/2022

  Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy while reducing side effects, announced the pricing of its initial public offering of 1,225,888 units of common stock and warrants, which priced at $8.125 per unit, raising gross proceeds of $9,960,340.

• Shuttle Pharmaceuticals Holdings, Inc. Announces Appointment of Chris Senanayake, PhD To Board of Directors

  5/20/2021

  Shuttle Pharmaceuticals Holdings, Inc., (Shuttle Pharma) a clinical stage company developing drugs to improve the treatment of cancer patients undergoing radiation therapy is pleased to announce the addition of Chris Senanayake , PhD as a member of its Board of Directors.

• Shuttle Pharmaceuticals, Inc. Awarded a New Patent for Dual Function HDAC Molecules for HDAC Inhibition and Ataxia Telangiectasia Mutated Activation for Cancer Treatment

  11/4/2020

   Shuttle Pharmaceuticals, Inc (Shuttle Pharma) a clinical stage, Maryland -based, biopharmaceutical company developing new drugs for cancer treatment in combination with radiation therapy, was awarded patent number 10,745,352 by the U.S. Patent and Trademark Office. These novel compounds enable cancer treatment by the combination o

• Shuttle Pharmaceuticals And POLA Pharma Agree To License U.S. Rights To Doranidazole

  8/16/2017